Amid rising power costs and humid weather, 5 star ceiling fans are seeing stronger demand across Indian homes. This list ...

Bristol Myers Squibb has expanded its push into radiopharma by licensing a prostate cancer therapy developed by Philochem for $350m upfront.

Viatris licenses two late-stage drugs from Idorsia for heart attack and lupus, both claimed to have blockbuster sales potential, for $350m upfront.